Hydrix Limited (HYD) Fair Value & Analysis
Technology · AU · Market cap A$2.9M
Fair value as of: Jun 26, 2026
From 8 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0800 to A$0.0041 (−94.9%) since Jun 24, 2026. Share price −40.0% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0040 – A$0.0307 · fair‑value band A$0.0040 – A$0.0042 · the A$0.0040 price screens below the A$0.0041 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Hydrix Limited (HYD) currently trades at A$0.0040, while our model-based Fair Value estimate is A$0.0041 — implying the stock looks roughly 2.6% undervalued today. We read business quality at 32/100 (below-average quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Hydrix Limited generated revenue of A$9.3M at a net margin of -57.4%. Revenue declined 13.6% year over year. Net debt stands at A$7.7M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Hydrix Limited, together with its subsidiaries, operates as a product design and engineering company in Australia, Europe, North America, Singapore, and internationally. It operates in three segments: Hydrix Services, Hydrix Medical, and Hydrix Ventures. The company offers product design and development consulting services comprising systems engineering, software, electronics, mechanical, human factors, and industrial design services; and product consulting services consisting of engineering design, development, prototyping, manufacturer management, and certification process management services. It also distributes cardiovascular products comprising Guardian, a heart attack warning system; and Implicity, a cloud-based AI-driven remote cardiac patient monitoring and data management software. In addition, the company invests in early stage medical technology (medtech) companies. It serves the cardiovascular, medtech, defence, and industrial industries. The company was formerly known …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hydrix Limited reported revenue of A$10.1M in FY2025 versus A$7.4M in FY2021, a compound +7.9%/yr. Reported net income was −A$2.9M in FY2025.
Is HYD fairly valued? → Check now
Similar stocks
6 more Scientific & Technical Instruments stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Keyence Corporation KYCCF | $457.38 | $228.86 | -50% |
| Keysight Technologies, Inc KEYS | $373.34 | $93.51 | -75% |
| Garmin Ltd GRMN | $231.72 | $186.06 | -20% |
| Chroma ATE Inc 2360 | 2,190 TWD | 337.05 TWD | -85% |
| Teledyne Technologies Incorporated TDY | $612.91 | $386.28 | -37% |
| Hexagon AB HXGBF | $8.84 | $5.23 | -41% |
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is Hydrix Limited (HYD) undervalued?
What is the fair value of HYD?
What is the quality score of HYD?
What is the revenue of Hydrix Limited (HYD)?
What is the net profit margin of HYD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.